HighTower Advisors
CCEL icon

HighTower Advisors’s Cryo-Cell International CCEL Stock Holding History

HighTower Advisors’s Portfolio CCEL Stock Details CCEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-13,761
Closed -$160K – 3438
2021
Q4 		$160K Buy
13,761
+1,000
+8% +$12.5K ﹤0.01% 2833
2021
Q3 		$155K Buy
+12,761
New +$157K ﹤0.01% 2770

Other funds holding CCEL

ICM
ISZO Capital Management New York $2M AUM 35.61% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.87B AUM 24.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCP
Seizert Capital Partners Birmingham, Michigan $2.17B AUM 11.2% 1-Year Est. Return
MCM
Maryland Capital Management Towson, Maryland $1.2B AUM 18.21% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

HighTower Advisors's CCEL Position: Q1 2022 in Review

HighTower Advisors sold out of Cryo-Cell International (CCEL) in Q1 2022, closing a stake of 13,761 shares — an estimated $160K sold.

HighTower Advisors first reported a position in CCEL in Q3 2021 and held it in 2 quarters. The position peaked at $160K in Q4 2021. 12 funds tracked by Wall St. Rank hold CCEL as of Q1 2022.

  • HighTower Advisors reported no remaining Cryo-Cell International position as of Q1 2022 after selling out during the quarter.
  • HighTower Advisors sold 13,761 Cryo-Cell International shares in Q1 2022, an estimated $160K.
  • HighTower Advisors first reported a position in Cryo-Cell International in Q3 2021 and held it in 2 quarters.
  • HighTower Advisors's Cryo-Cell International position peaked at $160K in Q4 2021.
  • 12 funds tracked by Wall St. Rank held Cryo-Cell International as of Q1 2022.

Based on HighTower Advisors's 13F filing for Q1 2022, filed 12 May 2022.